Toshiba at EuroCIS: Empowering Retailers to “Create Your Tomorrow”
At EuroCIS 2025, Toshiba Global Commerce Solutions showcases how it empowers retailers with its innovative solutions portfolio for smart stores, customer personalization, and security (booth in hall 9 #B42). The international trade fair will take place on February 18-20 in Düsseldorf, Germany.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250213535650/en/
The new TCx 820 all-in-one POS system is suitable for all types of store environments as it is available in various formats and screen sizes. (Photo: Business Wire)
“In a world brimming with possibilities, every retailer can shape their own future and deliver exceptional customer experiences and growth with the help of an experienced partner,” says Robin Lyon, Executive Director of Channels & Marketing, Toshiba Global Commerce Solutions. “To empower retailers to create their own tomorrow, Toshiba delivers complete solutions comprising of its modular MxP® hardware, software and services harnessing the power of AI, computer vision, and other transformative technologies. Advanced self-service solutions and new POS technologies are designed to meet the unique needs of retailers, no matter their size or segment.”
Innovative Solutions shown on the Toshiba booth
- Loss prevention and customer experience at self-checkout: The new Modular eXpansion Platform (MxP®) provides self-checkout solutions in a sleek design tailored for all retail segments. Various form factors feature capabilities for loss prevention and produce recognition using AI, computer vision and IoT sensors to recognize shrinkage and speed up transactions. Toshiba’s TCx® EDGEcam+ cameras monitor customer behaviors without in-store servers, enhancing security throughout the checkout area. For fast scan-free self-checkout, the MxP® VisionKiosk uses computer vision and AI to automatically identify items for a seamless shopping experience.
- Flexible POS-systems and versatile Touch Displays: The new TCx® 820 all-in-one POS-system and TCx® Touch Displays are available in multiple formats with a sleek design ready for all retail segments. They are configurable in five formats enabling seamless integration into any retail environment or use case. Screen sizes range from 10” to 24” with both landscape and portrait orientations available.
- Personalized shopping experiences: Catch Retail is an AI retail media platform for physical spaces, monetizing first-party data for retailers and brands, enabling them to reach new, targeted audiences in stores. Catch will demonstrate how they are revolutionizing in-store customer engagement, brand loyalty and revenue growth by enabling personalized media through various shopping touchpoints.
- AI-powered refrigeration management: Axiom Cloud will demonstrate how retailers can reduce energy consumption and save on maintenance costs in their cold chain operations using AI.
- Toshiba Commerce Marketplace: Aimed at meeting the ever-evolving needs of retail, the Toshiba Commerce Marketplace enables retailers to connect to an extensive network of industry-leading technology partners and solutions to stay competitive in an increasingly digital world, to enhancebusiness operations, and improve the shopping experience. Today, the Commerce Marketplace includes partners such as Adyen, Zebra, Datalogic, Ingenico, Ecrebo, Qualcomm, Honeywell, and Aptos, amongst others.
Toshiba will speak on the Blue and Red Stages
Toshiba experts will also share their knowledge and expertise on the EuroCIS stages:
February 18 at 11:40 - 12:00 on the Blue Stage (hall 10 G65)
The Business Benefits of Switching to a Secure Retail Cloud
Johnny Flynn, Retail Cloud Architect, Toshiba Global Commerce Solutions
February 19 at 14:00 - 14:20 on the Red Stage (hall 10 G01)
From Simple Break-Fix Maintenance to Sustainable Business Availability Management
Catherine Bataille, Director Professional Services, Toshiba Global Commerce Solutions
Dries de Beul, Technical Design & Solution Architect, Toshiba Global Commerce Solutions
To arrange to meet with Toshiba at EuroCIS, follow this link: Book a Meeting with Toshiba
About Toshiba Global Commerce Solutions:
Toshiba Global Commerce Solutions empowers retail to thrive and prosper through a dynamic ecosystem of smarter, more agile solutions and services that enable retailers to resiliently evolve with generations of consumers and adapt to market conditions. Supported by a global organization of devoted employees and partners, retailers gain more visibility and control over operations while enjoying the flexibility to build, scale, and transform retail experiences that anticipate and fulfill consumers’ ever-changing needs.
Visit commerce.toshiba.com and engage with us on:
LinkedIn - YouTube - Facebook - Instagram: @toshibacommerce
X/Twitter: @ToshibaCommerce
Toshiba Global Commerce Solutions is a wholly owned subsidiary of Toshiba Tec Corporation, which is traded on the Tokyo Stock Exchange.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250213535650/en/
Contacts
MEDIA CONTACT:
Toshiba Global Commerce Solutions
Robin Lyon
robin.lyon@toshibagcs.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press Release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press Release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 10:00:00 CET | Press Release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press Release
Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity. Pimicotinib, a colony stimulating factor-1 receptor (CSF-1R) inhibitor developed by Abbisko Therapeutics Co., Ltd., Shanghai, China, is the first Chemical Drug Class 1 approved in China for the treatment of TGCT. “We are continuing to deliver on our commitment to improving the lives of patients with rare tumors with this first-in-the-world regulatory approval of pimicotinib,” said Danny Bar-Zohar, CEO Healthcare and Member of the Executive Board of Merck. “This approval is a significant step forward in further strengthening our leadership in rare tumors, while offering patients the opportunity to change the course of
Incyte Japan Announces Approval of Minjuvi ® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press Release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom